IQ EQ FUND MANAGEMENT IRELAND Ltd Increases Position in CRISPR Therapeutics AG $CRSP

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 44.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 283,111 shares of the company’s stock after acquiring an additional 87,509 shares during the period. CRISPR Therapeutics accounts for about 1.2% of IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings, making the stock its 16th biggest position. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in CRISPR Therapeutics were worth $18,348,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CRISPR Therapeutics by 5.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after purchasing an additional 180 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of CRISPR Therapeutics by 24.6% during the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after purchasing an additional 181 shares during the period. Cerity Partners LLC grew its position in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after buying an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp increased its stake in CRISPR Therapeutics by 3.0% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after buying an additional 200 shares during the period. Finally, Ipswich Investment Management Co. Inc. raised its position in CRISPR Therapeutics by 0.9% during the 3rd quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company’s stock worth $1,633,000 after buying an additional 230 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada boosted their price target on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 11th. Chardan Capital cut their target price on CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating for the company in a research note on Wednesday, November 26th. Needham & Company LLC restated a “buy” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Finally, Bank of America cut their price objective on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Twelve investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $67.85.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the sale, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at approximately $8,082,926.23. This represents a 30.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Price Performance

CRSP opened at $45.88 on Friday. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The stock has a market cap of $4.37 billion, a P/E ratio of -8.21 and a beta of 1.72. The stock’s 50 day simple moving average is $54.83 and its 200 day simple moving average is $58.04.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.